No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Fulcrum Therapeutics Faces Genzyme Agreement Termination
Express News | Fulcrum Therapeutics Inc - Sanofi to Terminate Collaboration and License Agreement With Fulcrum
Fulcrum Therapeutics Jumps Amid Takeover Speculation
Shares Of Fulcrum Therapeutics See Volume; Traders Circulating Co. Mentioned By M&A Blog
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%